HER2 Gene Mutation Recruiting Phase 2 Trials for Trastuzumab emtansine (DB05773)

IndicationStatusPhase
DBCOND0081068 (HER2 Gene Mutation)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04620187Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasTreatment